Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication Nur Hezrin ShahrinCarol WadhamSusan Branford Chronic Myeloid Leukemias (V Oehler, Section Editor) Open access 06 August 2022 Pages: 171 - 180
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies John Joson NgS. Tiong Ong Chronic Myeloid Leukemias (V Oehler, Section Editor) 19 October 2022 Pages: 181 - 197
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions Emilia ScalzulliIda CarmosinoMassimo Breccia Chronic Myeloid Leukemias (V Oehler, Section Editor) 20 October 2022 Pages: 198 - 205
Value in Myeloma Care: Myth or Reality Evguenia OuchveridzeKatherine BergerGhulam Rehman Mohyuddin Health Economics (N Khera, Section Editor) 30 August 2022 Pages: 206 - 216
Precision Medicine in Myeloid Malignancies: Hype or Hope? Shristi Upadhyay BanskotaNabin KhanalVijaya Raj Bhatt Health Economics (N Khera, Section Editor) 16 August 2022 Pages: 217 - 227
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation Neel S. Bhatt Health Economics (N Khera, Section Editor) 04 October 2022 Pages: 228 - 242
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults Ginna GranrothNandita KheraCecilia Arana Yi Health Economics (R Mesa) Open access 19 September 2022 Pages: 243 - 253
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms Anmol BaranwalChristopher N. HahnDevendra K. Hiwase Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 20 August 2022 Pages: 254 - 265
Pediatric Germline Predisposition to Myeloid Neoplasms Christineil ThompsonSydney AriagnoMira A. Kohorst Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 19 September 2022 Pages: 266 - 274
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies Himachandana AtluriYoheved S. GersteinCourtney D. DiNardo Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 24 October 2022 Pages: 275 - 285
Bispecific Antibodies for the Treatment of Multiple Myeloma Scott R. GoldsmithShawn StreeterFahrettin Covut T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 27 August 2022 Pages: 286 - 297
Circulating Tumor DNA in Lymphoma Swetha KambhampatiJasmine Zain T-Cell and Other Lymphoproliferative Malignancies (R Mesa, Section Editor) 10 October 2022 Pages: 298 - 305
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma Arleigh McCurdyAlissa Visram Multiple Myeloma (Prashant Kapoor, Section Editor) 22 November 2022 Pages: 306 - 318
Molecular Pathogenesis of Myeloproliferative Neoplasms Benjamin RollesAnn Mullally Myeloproliferative Neoplasms (P Bose, Section Editor) 07 November 2022 Pages: 319 - 329
